CD64 binding potential does not translate into enhanced therapeutic efficacy for anti-IL-23 antibodies under physiologically relevant conditions

Abstract Background Interleukin (IL)-23 neutralizing antibodies are clinically efficacious but differ in the functionality of their Fc portion. Guselkumab (GUS) and ustekinumab (UST) have a wild-type (WT) Fc portion, permitting native binding to Fc gamma receptors (FcγRs), while risankizumab (RZB) l...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Joel F. Cohen-Solal, Calvin S. Pohl, Sheila M. Cummings, Jeremy P. Gygi, Zhaleh Safikhani, Brigitte Bartocha, Christopher D. Buckley, Yongli Dong, Killian Eyerich, Samuel D. Karsen, Grace R. Lynch, Michael Macoritto, Pierre A. Morisset, Ornella D. Nelson, Timothy Radstake, Florian Rieder, Jocelyn Rivas, John P. Savaryn, Kathleen M. Smith, Madison Stulir, Carmin Szynal, Casey Tylek, Geertruida M. Veldman, Laura G. Wasserman, Susan Westmoreland, Neha Chaudhary, Matthew M. Staron
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2026-03-01
Schriftenreihe:	Molecular Medicine
Schlagworte:	CD64 Crohn’s disease Fc portion FcγRI Guselkumab Inflammatory bowel disease
Online-Zugang:	https://doi.org/10.1186/s10020-026-01462-z
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!